Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : NRL-1 (diazepam) nasal spray act as inhibitory effects of gamma-aminobutyric acid (GABA), which is investigated for the treatment of epileptic seizures.
Product Name : Valtoco
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 18, 2023
Lead Product(s) : Pitolisant Hydrochloride
Therapeutic Area : Sleep
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BF2.649 (pitolisant hydrochloride) is an antagonist/inverse agonist that binds to the histamine H3 receptor, an autoreceptor located in the presynaptic region of the histamine-containing neurons in the human brain that plays a critical role in regulating...
Product Name : BF2.649
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 24, 2023
Lead Product(s) : Pitolisant Hydrochloride
Therapeutic Area : Sleep
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diazepam
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Neurelis
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Aculys Pharma signed licensing agreement with Neurelis, for the development and commercialization of VALTOCO (diazepam nasal spray), approved by the FDA in the United States for the acute treatment of seizure clusters in patients with epilepsy six years ...
Product Name : Valtoco
Product Type : Controlled Substance
Upfront Cash : Undisclosed
January 26, 2022
Lead Product(s) : Diazepam
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Neurelis
Deal Size : Undisclosed
Deal Type : Licensing Agreement